Stoke faces new doubts in search for ‘Spinraza for epilepsy’

Stoke Therapeutics on Tuesday revealed study results from a pair of small, mid-stage trials testing a medicine designed to target the underlying cause of Dravet Syndrome, a rare form of genetic epilepsy.